Allergy, Immunology, and ENT

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

The FDA has updated its approval for 1-mg epinephrine nasal spray, removing the age limit to allow all patients weighing at least 33 lb to access the treatment.

The approval marks the first FDA-authorized treatment for allergic fungal rhinosinusitis, with trial data showing significant improvements in outcome measures.

Phase trials show that Breztri Aerosphere triple therapy reduces annual severe exacerbation rates vs dual-combination inhaled therapy.

Global meta-analysis identifies eczema, delayed allergen introduction, and early antibiotics as key food allergy risk factors.

The FDA has issued a CRL for Anaphylm sublingual epinephrine, citing human factors and PK study needs; resubmission is anticipated in Q3 2026.

David Fleischer, MD, says phase 3 VITESSE results show the Viaskin peanut patch offers a safe, practical desensitization option for young children with peanut allergy.

Parents support early peanut introduction but remain confused about timing, purpose, and risks, highlighting the need for clearer pediatric guidance.

Phase 3 data show the Viaskin peanut patch improved desensitization vs placebo in children aged 4 to 7 years, supporting a planned FDA BLA in 2026.

Alice Hoyt, MD, FAAAI, underscored three core recommendations for improving pediatric food allergy management, emphasizing coordinated care and reliable access to epinephrine.

Alice Hoyt, MD, FAAAI, discussed the Early Childhood Anaphylaxis Collaborative’s efforts to improve anaphylaxis preparedness in early childcare settings.

He had no prior history of recurrent ear infections, abscesses, or boils. Can you guess the diagnosis?

Tezepelumab received FDA approval for CRSwNP in patients 12 years and older, supported by strong phase 3 data.

Training tools and EHR prompts boosted pediatricians’ adherence to early peanut introduction guidelines in a new trial.

Early allergen introduction, beginning in infancy and sustained over time, can safely reduce food allergy risk, said David Stukus, MD, at AAP 2025.

The clinical report replaces a 2010 report, as food allergy impacts up to 10% of children, with anaphylaxis estimated to occur in 1 in 15 schools per year.

Real-world evidence supports neffy as comparable to epinephrine injection in anaphylaxis care.

Study links early childhood eczema timing to risk of allergies like food allergy, asthma, and rhinitis, with five distinct disease phenotypes identified.

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

The federal agency has assigned a target action date of January 31, 2026, for a decision.

Prescriptions for the epinephrine nasal spray are now available for patients aged 4 years and up who weigh 33 to < 66 lbs.

The study involved 88 pediatric patients, with 12.5% showing positive intradermal test results and 1.1% positive subcutaneous provocation.

In 3 studies evaluating the effects of probiotics on eczema, probiotics groups reported a greater reduction in symptoms than placebo groups, but only when the allergy was IgE mediated.